# Consensus checked against original sources: MOTS-c as a Metabolic Healthspan Peptide

Cutoff: 9 October 2026. Consensus supports discovery and checks of specific source aspects; it is not a primary study, a full-paper audit or a causal probability meter.

## Mitochondrial genomic origin and translation compartment
Original Results0–1 report12S-region coding potential, NUMT searches and loss of immunodetected peptide/transcripts after rho0oractinonin depletion. Cytoplasmic translation is an inference from the standard versus mitochondrial genetic code; native export/translation was not directly tracked. Provider genome-origin wording should not become proof of mitoribosomal production or complete native assay validation. [Original PMID25738459](https://pubmed.ncbi.nlm.nih.gov/25738459/). Access: full_text_partial.

## Late-life dosing, functional healthspan and survival
Original Results6/8 verify male C57BL6/N functional gains and intermittent15mg/kg3times/week dosing beginning around23.5months. Overall survival is nonsignificant P=0.23. Food intake differs during late-life treatment, so the provider's no-hyperphagia description is not retained; a restricted early survival comparison is not whole-curve lifespan extension. [Original PMID33473109](https://pubmed.ncbi.nlm.nih.gov/33473109/). Access: full_text_partial.

## K14Q genotype and12S-rRNA structural alternative
Original Results0 predicts little12S-rRNA secondary-structure difference, not direct demonstrated structural perturbation as the provider states. Results6 shows female mouse WT/K14Q nulls, and cohort effects are sex/activity dependent. rRNA/linkedmtDNA effects remain possible rather than proven. [Original PMID33468709](https://pubmed.ncbi.nlm.nih.gov/33468709/). Access: full_text_partial.

## Direct target and native assay specificity
Original Results7/15/42 verify supplied-peptide SPR binding and CK2-dependent uptake through inhibitor/cellularASO controls. Muscle/adipose kinase effects differ and an input immunoblot has an acknowledged nonspecific band. Synthetic target binding supports pharmacology but does not validate every native ELISA signal. [Original PMID39559755](https://pubmed.ncbi.nlm.nih.gov/39559755/). Access: full_text_partial.

## Human exercise trans-organ flux
Complete original PubMed abstract verifies increased human interstitial peptide with no changed arterio-venous difference, plus mouse PGC1alpha/AMPK dependence of mitochondrial metrics. Provider muscle-source caution is supported, but absence of a gradient is not proof of zero muscle secretion. This source was examined at abstract depth, not full-text depth. [Original PMID41520850](https://pubmed.ncbi.nlm.nih.gov/41520850/). Access: abstract_metadata.

## Positive AMPK signal versus functional repair
Original Results3/5/7/11 show AMPK activation with adverse senescence/inflammatory changes and impaired repair after humanMSCpretreatment/transplantation in mice. This original negative-context test is missing from the provider synthesis and prevents signaling activation from being promoted to general regenerative benefit. [Original PMID42324588](https://pubmed.ncbi.nlm.nih.gov/42324588/). Access: full_text_partial.

## Human systemic-marker direction and mediation
Original Results5/19/22 show higher adult-obesity peptide measurements and no significant peptide change despite postsurgery metabolic/weight improvement. Abstract, body and table numeric summaries disagree, so the review retains direction/null status without an invented corrected value. Provider generalized deficiency framing is incomplete. [Original PMID41551324](https://pubmed.ncbi.nlm.nih.gov/41551324/). Access: full_text_partial.

## Opposite genotype-performance context
Complete original abstract reports higher muscle mass/grip among older Korean male C-allele carriers, with female nulls. This qualifies the provider's adverse-K14Q framing; observational population results are not proof of peptide dosing benefit or harm. [Original PMID39457696](https://pubmed.ncbi.nlm.nih.gov/39457696/). Access: abstract_metadata.

## Methods
Consensus was used to identify literature and cross-check specific claims about design, endpoints, scope and research gaps. Those aspects were checked against original primary abstracts/status records and selected original Methods/Results passages. Consensus output was not treated as original full text. Provider search omissions are not evidence that a study does not exist. Source access and examination receipts are retained. Scite use or monthly unavailability is recorded per case; provider citation counts do not change causal grades.